Last reviewed · How we verify
Definity infusion
Definity is an ultrasound contrast agent composed of perflutren-filled microbubbles that enhance echocardiographic imaging by increasing ultrasound backscatter from the left ventricular cavity.
Definity is an ultrasound contrast agent composed of perflutren-filled microbubbles that enhance echocardiographic imaging by increasing ultrasound backscatter from the left ventricular cavity. Used for Echocardiographic left ventricular opacification in patients with suboptimal echocardiograms, Improvement of left ventricular endocardial border definition.
At a glance
| Generic name | Definity infusion |
|---|---|
| Also known as | Perflutren Lipid Microspheres, (IND# 104397) |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
| Drug class | Ultrasound contrast agent |
| Modality | Small molecule |
| Therapeutic area | Cardiology / Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Definity microbubbles are injected intravenously and circulate through the heart chambers, where they reflect ultrasound waves more effectively than blood alone, improving visualization of cardiac structures and function. The microbubbles are stabilized by a lipid shell and are small enough to pass through the pulmonary circulation, allowing for both left and right heart opacification during echocardiography.
Approved indications
- Echocardiographic left ventricular opacification in patients with suboptimal echocardiograms
- Improvement of left ventricular endocardial border definition
Common side effects
- Headache
- Nausea
- Chest pain or discomfort
- Flushing
- Dyspnea
Key clinical trials
- Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy (EARLY_PHASE1)
- SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial (PHASE2)
- Ultrasound Therapy In Cardiac Amyloidosis (PHASE4)
- Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) (PHASE1)
- SHAPE for ICP Assessment (PHASE2)
- An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers (PHASE1, PHASE2)
- Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy (NA)
- Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: